The naloxone hydrochloride nasal spray will be made available over-the-counter, therefore not requiring a prescription, in an effort to reduce deaths from opioid abuse.
Finding a treatment for a skin disease that significantly diminishes the quality of life for those living with it has moved forward to the next phase of trials.
Progressive supranuclear-palsy (PSP) is a very rare brain disease and until recently, it was almost unheard of. Along with many neurodegenerative diseases, it has a high unmet medical need.
Small molecule drug, Niraparib combined with abiraterone acetate (AA) and prednisone (P) significantly reduces the risk of disease progression, or death, in patients with a type of prostate cancer, a consultant in Spain has said.
AMR joins a Series C funding raise for BioVersys, which is developing antimicrobials against common drug-resistant bacteria that threaten public health.
The FDA found traces of a nitrosamine in batches of vonoprazan, delaying the commercialization of the product and its application for an additional indication.
Clinical data findings from Actinogen’s Phase 2a study measuring the effects of Xanamem in patients with biomarker-positive Alzheimer’s Disease validated company’s ongoing program.
The company announces the submission of a 510(k) premarket notification application for its investigational inhaled nitric oxide delivery system for its INOmax gas product.
TransCelerate BioPharma continues to work towards “bringing new medicines to patients faster”. We caught up with the organization’s CEO to hear about its main achievements over the past decade and learn about what comes next.
Gladstone Institutes seek FDA approval for human clinical trial after single-dose, intranasal TIPs treatment for SARS-CoV-2 infection limits transmission in infected animals by decreased viral shedding.
In response to rising demand for inhalable treatments geard toward respiratory conditions, the company is adding capabilities and capacity at its Tampa site.
An expert from the company discusses how ever-changing patient needs and other dynamic factors are likely to impact pharma ingredient trends down the road.
The synthetic biology company which specializes in producing ingredients for plant-inspired medicines has a pilot-scale manufacturing facility in the works.
A company leader advises that the growing need for high-potency active pharmaceutical ingredients calls for CDMOs that consistently deliver quality at scale.
A representative from the R&D tech provider offers advice on how to wrangle with a stressful, complicated process for better results and fewer headaches.
This month’s news on technology, partnerships, expansions, and more includes items from IQVIA, Almac Group, Signant Health, Lonza, and other key companies.
This month’s announcements of appointments, partnerships, expansions, and mergers include Curia, Thread, TFF Pharmaceuticals, and other notable companies.
The contract development and manufacturing organization plans to invest €7.3m to expand and upgrade API production capacity at its Mourenx, France facility.
The contract development and manufacturing organization's active pharmaceutical ingredient manufacturing operation is located at its site in Aurora, Canada.
During BIO International, US leaders shared lessons learned from COVID-19, and how government and industry are collaborating to avoid future supply chain crises.
An expert from the organization discusses ahead of his CPhI North America presentation how tomorrow’s drugs can’t all be formulated with yesterday’s excipients.
An expert from Pharmatech Associates offers a glimpse into the evolution of CM and previews a lively discussion during the upcoming CPhI North America event.
A leader from the organizer of the pharmaceutical event discusses what’s in store for the upcoming conference, and for the drug development industry itself.
Introduced by two Republican Congressmen, the American Made Medicine Act is intended to boost domestic drug manufacturing and create jobs in the sector.
The 2022 edition of the Highly Potent Active Pharmaceutical Ingredients Summit (June 28 to 30 in Boston) will take on a range of topics, including safety.
Catalent has announced a multi-year $350m investment at its facility in Bloomington, Indiana, to expand biologics drug substance and drug product manufacturing capabilities.
The pharma manufacturing specialist is increasing capacity at its development and manufacturing labs to meet growing global demand for highly potent APIs.
The maker of active pharmaceutical ingredients for inhaled treatments is investing €9m ($9.8m USD) to expand its manufacturing plant in Barcelona, Spain.
This month’s news includes hiring, promotions, expansions, and acquisitions at H Clinical, Charles River, DHL Supply Chain, X-Chem, and other key companies.
The union of the active pharmaceutical ingredient supplier and contract development and manufacturing organization will create a global services company.
The excipients, equipment, and API companies have joined forces on Inhalation Together, an initiative aimed at advancing dry-powder inhalation solutions.
An executive from Rephine Catena discusses how pharmaceutical companies dealing with supply chain challenges could draw lessons from the food industry.
The latest news on software, manufacturing solutions, partnerships, and more includes IQVIA, TFF Pharmaceuticals, Quotient Sciences and other key companies.
An expert from the R&D tech provider discusses how automation, integration, and other tools can help with effective access and analysis of lab information.
This month’s announcements include hiring, expansion, and acquisition news from companies like DFE Pharma, ClinOne, Novartis, LEGO, Benchling, and more.
Returning to an in-person format March 21-24, the industry event is bringing a range of networking, educational, and social programming to New York City.
